{
  "ticker": "AFP",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02975667",
  "id": "02975667",
  "pages": 4,
  "price_sensitive": false,
  "date": "20250801",
  "time": "0730",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250801/pdf/06mdwygggfj5k9.pdf",
  "summary": "- **Revenue milestone**: Achieved record sales of $208 million (first time exceeding $200 million).  \n- **Geographic expansion**: Launched Maxigesic IV and Combogesic Rapid in the US; began sales of Maxigesic IV in Canada (addressable market >US$8 billion).  \n- **Financials**: Net debt reduced to $14.5 million (from $16.2 million); dividend increased to 1.8 cents/share (from 1.6 cents).  \n- **R&D pipeline**: 8 patented products in development, 24 off-patent injectables, and 5 programs nearing commercialization (e.g., Maxigesic variants, Crystaderm).  \n- **FY27 target**: Ambitious $300 million revenue goal.  \n\n*Note: No capital markets actions (e.g., raising, halt) or urgent trading signals identified.*",
  "usage": {
    "prompt_tokens": 1984,
    "completion_tokens": 184,
    "total_tokens": 2168,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-31T21:46:58.501346"
}